Heart Transplantation in High-Risk Recipients Employing Donor Marginal Grafts Preserved With <i>Ex-Vivo</i> Perfusion.

"Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"Università degli Studi di Udine 10.13039/501100008252"

"All consecutive high-risk patients who underwent HTx with grafts from marginal donors and preserved with EVP at the University Hospital of Udine and Hannover Medical School, from 2016 to 2021, were retrospectively analyzed. Indication for EVP was the same in the two centers and involved in all cases employment of a marginal graft for a high-risk recipient, as subsequently defined. The study was approved by the Institutional Review Board (Clinical Registration Number: 18386, 1 August 2016) and informed consent was waived due to its retrospective nature. The major end-point of the study was the assessment of early and mid-term clinical outcome in terms of survival and major complications after HTx."